Figure 6From: Clinical implications of novel activating EGFR mutations in malignant peritoneal mesotheliomaEGFR mutations are sensitive to Erlotinib treatment. Western blot analysis of COS-7 cell lines expressing MPM EGFR mutants following treatment with Erlotinib. Inhibition of EGFR phosphorylation and total EGFR levels were shown relative to controls treated with Erlotinib.Back to article page